 |
 |
|
|
     |
 |
|---|
 |
|
 |
|---|---|---|
|
|
||
|
|
|---|
|
|
The ScinoPharm Advantage ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. Combining cost-effective resources and productivity of Asia along with unmatched regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector.  News, Press Coverage, and Press Releases September 29, 2011 | ScinoPharm Taiwan, Ltd. Begins New Era as a Publicly Traded Company September 01, 2011 | ScinoPharm Appoints Patricia Chou as Chief Financial Officer and Vice President of Corporate Development April 01, 2011 | ScinoPharm Reports Final FY2010 Results February 08, 2011 | ScinoPharm to Provide Contract Manufacturing Service for Newly Approved Antidepressant Drug in the United States November 03, 2010 | ScinoPharm Receives Certification as an Authorized Economic Operator (AEO) Model Company August 31, 2010 | ScinoPharm to Invest in Tanvex Biologics March 25, 2010 | ScinoPharm Reports Final FY2009 Results; All-Time Highs for Revenue and Operating Profit November 19, 2009 | ScinoPharm Announces SafeBridge Potent Compound Safety Certification November 05, 2009 | ScinoPharm Breaks Ground for Changshu Plant July 30, 2009 | Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation November 25, 2008 | ScinoPharm Granted US Patent for Novel Crystal Forms July 10, 2008 | ScinoPharm Passes Japanese PMDA GMP Inspection October 15, 2007 | ScinoPharm Reports Record-high Performance February 26, 2007 | ScinoPharm’s 2006 Revenue and Net Income at Record High January 18, 2007 | ScinoPharm Launches More Cancer Treatment APIs in the US |
|
 |
||||||||||||||||||
|
|
